- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock | - | Investing.com | ||
| 28.03. | Bicara Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.03. | Bicara Therapeutics Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Stifel raises Bicara stock price target to $48, maintains Buy | 1 | Investing.com | ||
| 27.03. | Bicara Therapeutics Inc. Q4 Loss Misses Estimates | - | RTTNews | ||
| BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.03. | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | 82 | GlobeNewswire (Europe) | Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting... ► Artikel lesen | |
| 26.03. | Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.6% - Here's What Happened | 1 | MarketBeat | ||
| 25.03. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 | 1 | GlobeNewswire (USA) | ||
| 13.03. | Cantor Fitzgerald maintains Overweight on Bicara Therapeutics | 1 | Investing.com | ||
| 11.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 68 | GlobeNewswire (Europe) | BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients... ► Artikel lesen | |
| 27.01. | Bicara meldet positive Ergebnisse der Phase 1/1b-Studie für Krebstherapie | 1 | Investing.com Deutsch | ||
| 27.01. | Bicara reports positive Phase 1/1b trial results for cancer therapy | 1 | Investing.com | ||
| 27.01. | Bicara Therapeutics Inc.: Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium | 81 | GlobeNewswire (Europe) | BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients... ► Artikel lesen | |
| 13.01. | Bicara Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.01. | Bicara Therapeutics (NASDAQ:BCAX) Sets New 1-Year Low - What's Next? | 1 | MarketBeat | ||
| 02.01. | Bicara Therapeutics (NASDAQ:BCAX) Shares Down 2.9% - What's Next? | 2 | MarketBeat | ||
| 27.12.24 | Bicara Therapeutics (NASDAQ:BCAX) Trading Down 5.9% - Here's What Happened | 2 | MarketBeat | ||
| 12.11.24 | Bicara Therapeutics GAAP EPS of -$1.60 | 1 | Seeking Alpha | ||
| 12.11.24 | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | 243 | GlobeNewswire (Europe) | On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with... ► Artikel lesen |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 36,200 | -1,92 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen auf "Buy" mit einem Kursziel von 52 US-Dollar belassen. Analyst Tycho Peterson beschäftige sich in einer am Freitag... ► Artikel lesen | |
| EVOTEC | 5,900 | -0,08 % | RBC stuft Evotec auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Evotec mit einem Kursziel von 11,60 Euro auf "Outperform" belassen. Nach 15 sehr turbulenten Monaten dürfte der nächste wichtige... ► Artikel lesen | |
| TEMPUS AI | 46,220 | 0,00 % | Tempus AI, Inc. (NASDAQ:TEM) Sees Significant Increase in Short Interest | ||
| BIONTECH | 83,65 | -1,82 % | Lululemon | Ubisoft | Steyr - Curevac mit erstem Erfolg gegen Biontech | Markus Weingran - Mein Tipp: SMARTBROKER+: https://broker-tipp.de/ (Werbung) Willkommen bei der Börsenlounge mit Markus Weingran. Die Themen heute: Lululemon | Ubisoft | Steyr - Curevac mit erstem Erfolg... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,600 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 43,110 | -7,33 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 16,425 | 0,00 % | Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard | ||
| AVIDITY BIOSCIENCES | 28,120 | -5,54 % | Avidity Biosciences Inc Aktie: Neue Marktbedingungen, was bedeutet das? | Avidity Biosciences verzeichnete am Freitag einen Kursrückgang von 2,95 Prozent auf 31,60 USD. Trotz dieser kurzfristigen Schwäche konnte das Unternehmen im Monatsvergleich ein Plus von 7,67 Prozent... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 16,180 | -2,53 % | Arcutis Biotherapeutics, Inc.: Arcutis and Padagis Agree to Stay Patent Lawsuit | WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| OSR HOLDINGS | 2,430 | 0,00 % | OSR Holdings Inc.: OSR Holdings, Inc. (NASDAQ: OSRH) Enters Into $80 Million Common Stock Purchase Agreement With White Lion GBM Innovation Fund, With An Eye Towards Leveraging Innovate GBM's Non-Profit Ecosystem to Accelerate ... | SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- OSR Holdings, Inc. ("OSR") (NASDAQ: OSRH), a global healthcare company focused on advancing innovative therapies... ► Artikel lesen | |
| BB BIOTECH | 30,450 | -2,87 % | BB Biotech Aktie: Gibt es jetzt Probleme? | Die BB Biotech AG kämpft aktuell mit einem erheblichen Wertverlust. Die Aktie notiert bei 31,85 CHF und hat innerhalb der letzten Woche einen Rückgang von 8,08% verzeichnet. Im Monatsvergleich fällt... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,800 | 0,00 % | Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March | ||
| CG ONCOLOGY | 18,750 | -16,41 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,470 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 13,415 | +2,80 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen |
BICARA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 11,890 Euro und damit -10,94 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BICARA THERAPEUTICS INC finden Sie auf Wallstreet Online.
